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Purpose: The dipeptidyl peptidase IV (DPPIV) gene family exhibits multiple 
functions and is involved in the pathogenesis of various diseases. It has attracted 
pharmaceutical interest in the areas of metabolic disorders as well as cancer. How-
ever, clinicopathologic significance of DPPIV family in colorectal cancer is not 
fully understood. Materials and Methods: The clinical relevance of DPPIV and 
DPP10 expression was determined by immunohistochemical staining, and by as-
sessing its clinicopathologic correlation in 383 colorectal cancer patients with 
known clinical outcomes. Results: DPPIV was not expressed in normal colon mu-
cosa, but it showed luminal expression in 52 of the 383 colorectal cancers 
(13.5%). DPPIV expression in tumors was associated with right-sided location of 
the colon (p=0.010) and more advanced tumor stage (p=0.045). DPP10 was ex-
pressed in normal colonic mucosa, but its expression varied in primary colorectal 
cancer tissues. Loss of DPP10 expression was found in 11 colorectal cancers 
(CRCs) (2.9%), and multivariate analysis showed that loss of DPP10 expression 
was an independent factor for poor patient prognosis (p=0.008). Conclusion: 
DPP10 may play a role in disease progression of colorectal cancer and loss of 
DPP10 expression in primary CRC is significantly associated with poor survival 
outcomes.
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INTRODUCTION
Colorectal cancer is the third most common malignancy in Western countries1 
and in South Korea.2 Despite remarkable advances in diagnostic and therapeutic 
modalities, 20% of patients are still diagnosed with colorectal cancer at a far ad-
vanced stage, with distant metastasis, and these patients have a 5-year survival 
rate of only 12%.3 In order to reduce cancer incidence and mortality rate, early 
detection with appropriate therapeutic management is necessary. Molecular bio-
marker for cancer may be helpful for diagnosis, prediction of prognosis or thera-
peutic target.4 
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of those 383 patients were reviewed. These 383 patients in-
cluded 152 women and 231 men, with a mean age of 58 
years (range, 25 to 86 years), and a mean follow-up time of 
64 months (range: 2-74 months). Liver metastasis was 
identified in 90 patients, 69 with synchronous and 21 with 
metachronous metastasis, with a mean metastasis duration 
of 19 months (range, 1 to 67 months). All patients were 
classified according to World Health Organization criteria 
and staged according to the 2009 American Joint Commit-
tee on Cancer. 
For Western blot analysis, tissue samples were obtained 
from 10 colorectal cancer patients with synchronous liver 
metastases, who underwent surgical resection at the Nation-
al Cancer Center, Korea. We obtained four tissue samples 
from each patient: normal colonic mucosa, primary colorec-
tal cancer, normal liver, and liver metastasis.
Informed consent was obtained from all of the enrolled 
patients. This study was approved by the Institutional Re-
view Board of the National Cancer Center of Korea.
Immunohistochemistry
Immunostaining was performed using the labeled streptavi-
din-biotin complex method. After antigen retrieval, the sam-
ples were incubated with mouse monoclonal anti-DPPIV 
(CD26) antibody (ready-to-use; MBL, Nagoya, Japan), rab-
bit polyclonal anti-DPP10 antibody (dilution 1 : 500; Abcam, 
Cambridge, UK), and mouse monoclonal anti-carcinoembry-
onic antigen (CEA) antibody (clone C-II, dilution 1 : 200; 
DAKO, Carpinteria, CA, USA). As a negative control, the 
tissue sections were incubated with Tris-buffered saline 
alone, without the primary antibody. DPPIV expression 
was mainly identified in luminal borders or as an intralumi-
nal secretory pattern. The staining results for DPPIV were 
classified as positive if any secretory expression was dis-
cernible. There was no reported immunostaining criterion 
of DPP10 loss. At first, DPP10 staining was quantified us-
ing H score20 by multiplying the staining intensity by the 
percentage of stained tumor cells. Staining intensity was 
classified as 1 for weak, 2 for moderate, or 3 for strong 
staining. H scores ranged from 0 to 300. Then, in order to 
determine a cutoff value of H score, Kaplan-Meier analysis 
was performed according to groups with DPP10 H scores 
of 0-20, 21-50, 51-100, 101-150, 151-200, 201-250, and 
>250. As for CEA, the staining pattern was classified into 
0, no expression; 1+, focal expression along the luminal 
border; 2+, partial membranous expression along the lumi-
nal and cytoplasmic borders; or 3+, diffuse membranous 
The dipeptidyl peptidase IV (DPPIV) gene family has 
garnered increasing interest due to its diverse functions re-
lated to pathogenesis of inflammatory, metabolic, and endo-
crine disorders, and cancer progression.5 DPPIV inhibitors 
have merged as successful therapeutic targets for type 2 di-
abetes mellitus and the application of dipeptidyl peptidase 
inhibitors in pathogenic conditions, such as cancer, has 
been carefully considered.5 The DPPIV gene family be-
longs to the prolyl oligopeptidase family of enzymes5 and 
comprises proteins with DPP enzymatic activity and DPP4 
structural homologues.6 To date, eight DDP peptidases have 
been identified, DPP3, DPPIV, DPP6, DPP7, DPP8, DPP9, 
DPP10, and fibroblast activation protein.7 DPPIV is the 
best-studied member of this family, and had been shown to 
be involved in cell differentiation, adhesion, immunomodu-
lation, and apoptosis, all critical for controlling neoplastic 
transformation.8-10 Also, decreased expression of DPPIV 
has been reported in various malignancies.8,10-13 
DPP10 is a newly cloned peptidase with structural simi-
larity to DPPIV.14 DPP10 lacks DPP4-like enzyme activity 
due to a point mutation in its active site, where a serine is 
replaced by a glycine residue.14 It binds to specific voltage-
gated potassium channels, altering their structures and bio-
physical properties,15 but the cellular functions of DPP10 
remain unknown. DPP10 has been linked to asthma sus-
ceptibility by several genome-wide association studies,16,17 
and recently impaired expression of DPP10 gene in malig-
nant mesothelioma18 and nasopharyngeal carcinoma has 
been reported.19
In the present study, we evaluated protein expression of 
DPPIV and DPP10 in colorectal cancer tissue using immu-
nohistochemistry and compared their expression with clini-
cal relevance. We found that loss of DPP10 expression in 
primary colorectal cancer is significantly associated with 
poor survival outcomes. We further evaluated the level of 
protein expression of DPP10 using western blot in selected 
colorectal cancer tissues.
MATERIALS AND METHODS
　　　
Collection of colorectal cancer tissue samples
For immunohistochemical analysis, tissue microarray blocks 
were constructed from formalin-fixed paraffin-embedded 
tissues of 383 patients with colorectal cancer who under-
went surgical resection at the National Cancer Center of 
Korea in 2003. The clinical charts and pathological reports 
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on Western blotting. p-values <0.05 were considered statisti-
cally significant. All statistical analyses were performed us-
ing SPSS ver. 17.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
 
Clinicopathological analysis of DPPIV expression in 
colorectal cancer 
DPPIV was not expressed in normal colon mucosa (Fig. 1). 
Fifty-two (13.5%) out of 383 primary colorectal cancers 
showed DPPIV expression (Fig. 1). DPPIV expression in tu-
mors was significantly associated with right-sided location of 
the colon (p=0.008) and more advanced T stage (p=0.047) 
(Table 1), but there was no significant relationship with oth-
er clinical parameters including distant metastasis or sur-
vival benefit. 
Clinicopathological analysis of DPP10 expression in 
colorectal cancer 
DPP10 was expressed in normal large intestinal mucosa, 
but its expression varied in colorectal cancers (Fig. 2). The 
mean±standard deviation of H score for colorectal cancers 
was 157.19±77.69 (range 0 to 295). In order to determine 
the cutoff score of DPP10 for clinical significance, Kaplan-
Meier analysis was performed according to groups with 
DPP10 H scores of 0-20, 21-50, 51-100, 101-150, 151-200, 
201-250, and >250. There was a gap in clinical outcomes 
between tumors with a DPP10 score of 20 or less and those 
with a DPP10 score above 20. Therefore, loss of DPP10 
was defined as a DPP10 H score of 20 or less. According to 
this criterion, 11 (2.9%) out of 383 primary colorectal can-
cers showed loss of expression. Loss of DPP10 was signifi-
cantly associated with female preponderance (p=0.023) and 
diffuse CEA expression in the primary tumor (p=0.037) 
(Table 1). However, loss of DPP10 expression was not as-
and cytoplasmic expression. For statistical analysis, 3+ was 
defined as ‘high’ and 0 to 2+ were defined as ‘low’. All im-
munohistochemical staining results were evaluated inde-
pendently by two pathologists (HSP and HJC).
Western blotting
Western blot analysis was performed as described.21 Briefly, 
4000×g supernatant fractions of cell homogenates contain-
ing equivalent amounts of protein were subjected to sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE). The proteins were transferred to polyvinylidene 
fluoride membranes (Millipore, Bedford, MA, USA), fol-
lowed by blocking for 2 h at 4°C in 1% Tween 20-TBS 
buffer containing 1.5% non-fat dry milk (Bio-Rad, Rich-
mond, CA, USA) and 1 mM MgCl2. The membranes were 
incubated for 2 h at room temperature with primary anti-
body against DPP10 (Abcam, UK), washed three times for 
15 minutes each with blocking solution and incubated with 
diluted horseradish peroxidase-conjugated secondary anti-
body (SouthernBiotech, Birmingham, AL, UK) for 1 hour 
at room temperature. The membranes were washed three 
times for 15 min each with blocking solution and incubated 
with WEST-ZOL (plus) chemiluminescence reagent (iN-
tRON Biotechnology, Seoul, Korea) for 1 minute and ex-
posed to film (Kodak Blue XB-1, Rochester, NY, USA).
Statistical analysis
The χ2-test was used to evaluate the relationship between 
immunohistochemical expression of DPPIV and DPP10 and 
clinicopathological features. Cancer-specific or disease free 
survival was estimated using the Kaplan-Meier method and 
compared with the log-rank test. The prognostic value of 
protein expression was determined by multivariate analysis 
using the Cox proportional hazards regression model. The 
non-parametric Mann-Whitney U test was used to calculate 
between-group differences in DPPIV and DPP10 expression 
Fig. 1. Immunohistochemistry of DPPIV in primary colorectal cancers (×200). (A) Normal crypt epithelium did not express DPPIV protein. (B) Some colorectal 
cancers showed intraluminal expression of DPPIV. (C) Rare colorectal cancers showed focal cytoplasmic expression of DPPIV. DPPIV, dipeptidyl peptidase IV.
A B C
DPP10 Expression in Colorectal Cancer
Yonsei Med J   http://www.eymj.org   Volume 54   Number 6   November 2013 1365
Western blot of DPP10 in 10 quadruplet samples from 
patients with colorectal cancer
In order to confirm down-regulation of DPP10 in colorectal 
cancer compared to normal tissue, we performed western 
blot analysis of DPP10 in quadruplet samples of colorectal 
cancer with synchronous liver metastasis. DPP10 protein 
has two isoforms: isoform 1 with a molecular size of 90934 
Da, and isoform 2 with a molecular size of 90186 Da.7 
Western blotting of fresh samples of matched normal co-
sociated with pT, pN, or pM stage. Univariate survival 
analyses showed that patients with tumors retaining DPP10 
expression had significantly longer cancer-specific 
(p=0.013) and progression-free (p=0.0475) survival than 
patients with tumors that did not express DPP10 (Fig. 3). 
Multivariate analyses showed that loss of DPP10 expres-
sion was an independent poor prognostic factor for cancer-
related death (p=0.001) and disease recurrence (p=0.002) 
(Table 2).
Table 1. Association between DPPIV and DPP10 Expression in 383 Primary Tumors and Clinicopathologic Parameters
Clinicopathologic parameters
DPPIV expression DPP10 expression
Absent (%) Present (%) p value Loss (%) Retained (%) p value
Sex
Male 199 (60.1) 32 (61.5)
0.846
  3 (27.3) 228 (61.3)
0.023
Female 132 (39.9) 20 (38.5)   8 (72.7) 144 (38.7)
Location
Right   82 (24.8) 22 (42.3)
0.008
  2 (18.2) 102 (27.4)
0.497
Left 249 (75.2) 30 (57.7)   9 (81.8) 270 (72.6)
Tumor grade
Low 294 (88.8) 46 (88.5)
0.939
10 (90.9) 330 (88.7)
0.820
High   37 (11.2)   6 (11.5) 1 (9.1)   42 (11.3)
Tumor border
Expanding 148 (44.7) 29 (55.8)
0.137
  3 (27.3) 174 (46.8)
0.201
Infiltrative 183 (55.3) 23 (44.2)   8 (72.7) 198 (53.2)
Lymphatic invasion
Absent 120 (36.3) 21 (40.4)
0.566
  3 (27.3) 138 (37.1)
0.506
Present 211 (63.7) 31 (59.6)   8 (72.7) 234 (62.9)
Vascular invasion
Absent 215 (65.0) 33 (63.5)
0.834
  9 (81.8) 239 (64.2)
0.229
Present 116 (35.0) 19 (36.5)   2 (18.2) 133 (35.8)
Lymphocytic infiltration
Absent 303 (92.4) 46 (90.2)
0.591
10 (90.9) 339 (92.1)
0.884
Present 25 (7.6) 5 (9.8) 1 (9.1) 29 (7.9)
Stage*
I, II 127 (38.4) 23 (44.2)
0.421
  4 (36.4) 146 (39.2)
0.847
III, IV 204 (61.6) 29 (55.8)   7 (63.6) 226 (60.8)
pT*
T1, T2   54 (16.3) 3 (5.8)
0.047
1 (1.8)   56 (98.2)
0.584
T3, T4 277 (83.7) 49 (94.2) 7 (3.0) 226 (97.0)
pN*
N0 135 (40.8) 24 (46.2)
0.465
4 (2.5) 155 (97.5)
0.725
N1, N2 196 (59.2) 28 (53.8) 7 (3.1) 217 (96.9)
pM*
M0 240 (72.5) 37 (71.2)
0.839
7 (2.5) 270 (97.5)
0.513
M1   91 (27.5) 15 (28.8) 4 (3.8) 102 (96.2)
Tissue CEA expression 
  in primary tumor
Low 166 (50.2) 22 (42.3)
0.293
  2 (18.2) 186 (50.0)
0.037
High 165 (49.8) 30 (57.7)   9 (81.8) 186 (50.0)
DPPIV, dipeptidyl peptidase IV; CEA, carcinoembryonic antigen.
*According to American Joint Committee on Cancer TNM staging system.
Fig. 2. Immunohistochemistry of DPP10 in primary colorectal cancers (×200). (A) Normal crypt epithelium showed mild DPP10 expression in cytoplasm. (B) 
Most colorectal cancers retained DPP10 expression. (C) Some colorectal cancers showed loss of DPP10 expression. DPP, dipeptidyl peptidase.
A B C
Heae Surng Park, et al.
Yonsei Med J   http://www.eymj.org   Volume 54   Number 6   November 20131366
did than did not express DPP10 transcripts.18 DPP10 gene 
has reported to be down-regulated in nasopharyngeal can-
cer.19 Similarly, we found that loss of DPP10 immunostain-
ing in primary colorectal tumors was associated with signif-
icantly poorer cancer-specific and disease-free survival 
outcomes, although the number of cases with DPP10 loss 
was small. The exact role of DPP10 in colorectal cancer is 
unknown, but it may affect tumor cell survival or growth as 
it modulates potassium channel function, which is crucial 
in regulating cell proliferation, cell cycle progression, and 
apoptosis.14,22 Loss of DPP expression by a primary carci-
noma was not associated with liver metastasis in the pres-
ent study.
DPPIV was originally identified as a T cell differentiation 
antigen (CD26) and it is 110-kDa glycoprotein with an ex-
tracellular domain possessing ectopeptidase activity.21 This 
enzyme cleaves X-Pro dipeptides from the N-terminal end 
of peptides and proteins, inactivating or degrading mitogen-
ic growth factors and neuropeptides.9 DPPIV expression 
had been identified in various cell types including on lym-
lon-primary colon cancer-normal liver-liver metastasis tak-
en from 10 patients with colorectal cancer revealed various 
levels of expression of DPP10 protein in these samples (Fig. 
4A). However, the level of expression of DPP10 was signif-
icantly lower in primary tumor than in normal colonic mu-
cosa (p=0.018) (Fig. 4B).
DISCUSSION
In the present study, we identified DPP10 as a candidate 
protein related to colorectal cancer progression, and to our 
knowledge, this is the first study on the role of DPP10 in 
colorectal cancer. Western blot analysis showed that DPP10 
expression was decreased in tumors compared with normal 
tissue. Few studies to date have assessed the association be-
tween DPP10 and cancer. A large deletion in the DPP10 
gene, producing a truncated fusion transcript, was reported 
in patients with malignant mesothelioma, and overall sur-
vival was significantly longer in patients with tumors that 
Table 2. Multivariate Survival Analysis in 383 Colorectal Cancer Patients
Pathological parameters
Cancer-specific survival Progression-free survival
HR 95% CI p value HR 95% CI p value
DPP10 expression: lost vs. retained 0.272 0.118-0.627 0.002 0.191 0.065-0.558 0.002
pT: T1, T2 vs. T3, T4 5.426   0.733-40.164 0.098 1.816 0.637-5.177 0.265
pN: N0 vs. N1, N2 1.387 0.718-2.679 0.330 1.668 0.879-3.167 0.118
pM: M0 vs. M1 9.274   5.455-15.768 <0.0001 2.877 1.743-4.751 <0.0001
Histologic grade:  low vs. high 2.690 1.587-4.558 <0.0001 1.689 0.852-3.348 0.133
Vascular invasion: absent vs. present 1.575 0.978-2.537 0.062 3.085 1.814-5.247 <0.0001
Lymphatic invasion: absent vs. present 1.520 0.857-2.697 0.152 1.544 0.866-2.753 0.141
Tissue CEA expression: absent vs. present 1.228 0.814-1.855 0.328 1.129 0.722-1.767 0.594
HR, hazard ratio; 95% CI, 95% confidence interval; CEA, carcinoembryonic antigen.
Fig. 3. Kaplan-Meier survival curves according to the DPP10 expression in 383 colorectal cancer patients. Loss of DPP10 expression in primary tumor was 
significantly associated with worse cancer-specific (A) and progression-free (B) survival. DPP, dipeptidyl peptidase.
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level has been reported in colorectal cancer patients, com-
pared to benign or non-neoplastic colorectal disease 
groups.29 In the present study, we did not observe DPPIV 
expression in normal colonic epithelial cells, but focal aber-
rant expression of DPPIV was present in colorectal cancer 
tissues as the secretory form within cancer glandular lumen, 
but the expression was not relevant to clinicopathologic 
findings except for right-side location (p=0.010). Fric, et 
al.30 reported similar results showing a higher expression of 
DPPIV in sporadic right colon cancer than in left colon 
cancer. However, our results do not suggest that DPPIV 
plays a role in colorectal cancer, in terms of the frequency 
and localization of the protein expression. Indeed, intracel-
lular expression of DPPIV was rare in our cases. Taking 
into consideration that DPPIV can be originated from vari-
ous cell types, DPPIV level in serum may not reflect the 
phocytes, melanocytes, epithelial brush borders of the intes-
tine, kidney, and pancreas duct, and liver hepatocytes.8,23,24 
DPPIV is multifunctional and has merged as a new thera-
peutic target for type 2 diabetes.5 DPPIV expression has been 
reported to be decreased in various malignancies, including 
nonsmall cell lung cancer cell lines,11 melanoma cells,8 
metastatic prostate cancer cells,10 and high grade endome-
trial carcinomas.12 Restoration of DPPIV expression in can-
cer cell lines resulted in a change of cell phenotype, to a 
nonmalignant or differentiated phenotype,8,10,11 suggesting 
that DPPIV may play a role in tumor suppression. However, 
it has been also reported to be upregulated in lung adenocar-
cinoma,25 prostate carcinoma,26 and thyroid carcinoma.27 In 
colorectal cancer, variable expression of adenosine deami-
nase complexing protein (the identical protein of DPPIV) 
has been reported28 and recently, decreased serum DPPIV 
Fig. 4. Western blot of DPP10 in 10 colorectal cancer patients with synchronous liver metastasis. (A) Western blotting of matched normal colon, primary 
colorectal cancer, and liver metastasis from 10 selected patients showed variable expression of DPP10. (B) Level of expression of DPP10 in primary colorec-
tal cancer was significantly decreased. N, normal; T, tumor; DPP, dipeptidyl peptidase; OD, optical density.
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To our knowledge, this is the first study describing the 
role of DPP10 in colorectal cancer with its prognostic sig-
nificance. However, our study has limitations, including the 
retrospective evaluation, small number of positive cases, 
and the lack of more distinct functional or molecular evi-
dence for the role of DPP10 in colorectal cancer progression. 
In conclusion, our results suggest that DPP10 might play a 
role in the progression of colorectal cancer, and may be an 
independent prognostic marker in patients with colorectal 
cancer. Further studies to clarify the underlying molecular 
mechanism of the role of DPP10 in colorectal cancer are 
needed. 
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